Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• The DNA damage response (DDR) pathway is crucial for maintaining genomic stability.
• Defects in DDR pathways can lead to cancer susceptibility and resistance.
• Aberrant protein expression within DDR, particularly DNA repair, is linked to cancer cell survival.

Purpose of the Study:

• To review the development of small molecule inhibitors targeting key DDR proteins.
• To explore the therapeutic implications of these inhibitors in cancer treatment.
• To summarize their mechanisms of action in preclinical and clinical settings.

Main Methods:

• Literature review of small molecule inhibitors targeting DDR proteins.
• Analysis of preclinical studies on DDR inhibitor efficacy.
• Examination of clinical trial data for DDR inhibitors in monotherapy and combination treatments.

Main Results:

• Small molecule inhibitors targeting DDR proteins show significant therapeutic potential.
• These inhibitors can be used as monotherapy or in combination with chemotherapy or checkpoint inhibitors.
• Understanding the action mode of DDR inhibitors is key to optimizing cancer therapy.

Conclusions:

• Targeting DDR proteins with small molecule inhibitors is an effective cancer therapeutic strategy.
• Further research into DDR inhibitors can lead to novel cancer treatments.
• Combination therapies involving DDR inhibitors demonstrate promise for overcoming cancer resistance.